title: Comparison of two oxytocin administration protocols in elective cesarean section: 5 iu versus 10 iu.
abstract: Background Although Oxytocin is used systematically during caesarean section, no recommendation precise optimal dose for this indication. The bolus administration of 10 IU intravenously after extraction of the newborn, is accompanied by side effects mainly hemodynamic. Objectives To compare two Oxytocin protocols:  05 IU bolus Vs. 10 IU bolus during Cesarean section by studying their respective effectiveness (effects on uterine tone) and adverse effects. Methods A prospective randomized double-blind study including 87 term parturients for undergoing a C-section under loco regional anesthesia. Parturients were randomized into two groups depending on the injected Oxytocine dose : - Group 1 (n = 43): 10 IU + 25 IU IVD in 500 ml of serum / 3h - Group 2 (n = 44): 5 IU IVD + 25 IU in 500 ml serum / 3h. Results The variation of the heart rate and the incidence of low blood pressure were significantly greater for Group 1. No significant differences between the two groups regarding blood loss was noticed per or postoperatively. The type of digestive side effects were more common in the first group. Conclusion Administration of 5 units of Oxytocin during the scheduled C-sections is effective for uterine tone without superimposed bleeding risk, guarantees better hemodynamic stability and less side effects than the 10 units dose.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Derbel
authors.forename: Dhia
authors.initials: D
authors.lastname: Mekki
authors.forename: Abir
authors.initials: A
authors.lastname: Riahi
authors.forename: Kaouther
authors.initials: K
authors.lastname: Dimassi
authors.forename: Mhamed Sami
authors.initials: MS
authors.lastname: Mebazaa
authors.forename: Mohamed Faouzi
authors.initials: MF
authors.lastname: Gara
mesh_terms: D000328:Adult; D000765:Anesthesia, Conduction / Q000379:methods; D016063:Blood Loss, Surgical / Q000706:statistics & numerical data; D002585:Cesarean Section / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D010120:Oxytocics / Q000008:administration & dosage* / Q000009:adverse effects; D010121:Oxytocin / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011446:Prospective Studies
chemical_list: D010120:Oxytocics; D010121:Oxytocin